beyond anthracyclines and trastuzumab: cardiotoxicity of novel agents
Published 1 year ago • 178 plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
1:47
safe: cardiotoxicity prevention in breast cancer treated with anthracyclines and/or trastuzumab
-
1:55
investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in her2 ebc
-
40:04
jacc: cardiooncology video case presentation: cardiotoxicity during her2-targeted therapy
-
1:14
updated analysis from mountaineer: tucatinib and trastuzumab for her2-positive mcrc
-
4:29
pertuzumab, trastuzumab and cyclophosphamide in older patients with her2 breast cancer
-
21:46
living with a history of triple-negative breast cancer
-
2:29
mountaineer: tucatinib plus trastuzumab for her2 metastatic colorectal cancer
-
47:13
newly diagnosed with metastatic breast cancer
-
2:22
dr. tripathy on the treatment of breast cancer with anthracyclines and trastuzumab
-
2:43
lilac: comparing cardiac safety of abp 980 with trastuzumab
-
0:50
investigating mechanisms of resistance to cdk4/6 inhibitors
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
1:11
development of antibody-drug conjugate therapies in breast cancer
-
6:58
cardiotoxicities of antineoplastic medications
-
1:59
adapt: de-escalated neoadjuvant pertuzumab trastuzumab with or without paclitaxel in hr-/her2 ebc
-
1:09
trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel metastatic her2 breast cancer
-
1:47
her2climb-05: tucatinib trastuzumab and pertuzumab as maintenance therapy for her2 metastatic bc
-
5:51
the aphinity trial
-
2:01
her2climb: tucatinib in combination w/ capecitabine & trastuzumab
-
12:03
anthracycline chemotherapy side effects: cardiotoxicity in breast cancer explained
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
1:48
selpercatinib induced durable efficacy in ret fusion-positive nsclc